| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
LA JOLLA, Calif.—In a new study reported on this summer, scientists at The Scripps Research Institute (TSRI) identified drug candidates that can boost a cell’s ability to catch the “typos” in protein production that can cause a deadly disease called amyloidosis.
 
“This study reveals a new approach to intervene in human disease,” said Luke Wiseman, assistant professor at TSRI and co-senior author of the new research with Jeffery Kelly, the Lita Annenberg Hazen Professor of Chemistry at TSRI.
The research was published today in the journal eLife.
 
As TSRI explained, every human cell houses a little factory called the endoplasmic reticulum (ER), where proteins are folded into their proper three-dimensional shape before exiting a cell. When the ER notices a typo in these proteins—a misfolding event—it recruits chaperone proteins to catch the misfolded proteins before they enter the bloodstream and form toxic clusters, or amyloid. Amyloid deposits in the heart, liver, retina or other organs in amyloidosis diseases lead to the degeneration of these tissues.
 
But there are not always enough chaperones to catch all misfolded proteins. To fix this, scientists are looking at possible strategies to activate the ER’s unfolded protein response (UPR), a signaling network that tells cells to produce more chaperone proteins to enhance editing or protein quality control.
 
“We’re trying to make these helpers more efficient,” said Kelly, who also serves as chairman of the Department of Molecular and Experimental Medicine and is a member of the Skaggs Institute for Chemical Biology at TSRI. But there’s a catch to this approach—the cell will die if all three signaling “arms” of the UPR are activated for too long.
 
However, a 2014 study from the Wiseman and Kelly labs indicated there may be a way to activate just one “arm” of the UPR, the ATF6 pathway, to catch misfolded proteins without triggering cell death. For the new study, the researchers teamed up with TSRI’s Molecular Screening Center, on the institute’s Florida campus, to pursue this potential approach to developing new therapies.
 
“Now we can fine-tune the ER quality-control process,” said Lars Plate, a TSRI research associate who was co-first author of the study with Christina B. Cooley, a TSRI research associate at the time of the study, who is now an assistant professor at Trinity University.
 
The next steps will be to test several other small molecules as potential drug candidates and develop models to study these compounds in different diseases where protein secretion plays a role.
 
“This is a class of drugs that could also work for diabetes and additional neurodegenerative diseases linked to protein misfolding, like Alzheimer’s disease,” said Kelly.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist using a digital tablet with futuristic data visualization graphics overlaying the screen, representing advanced laboratory data management and analysis

Unlocking laboratory efficiency: a complete guide to LIMS selection

Discover how to choose, implement, and optimize laboratory information management systems (LIMS) to streamline lab operations and ensure compliance.
Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue